Leukemia News

The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat certain adults or children with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.

The FDA granted fast track designation to SNDX-5613 for the treatment of adults and children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia with certain genetic markers.

In this video, Aaron T. Gerds, MD, from the Cleveland Clinic Taussig Cancer Institute, discusses a new IDH inhibitor, olutasidenib, which was found to be well tolerated in patients with relapsed or refractory acute myeloid leukemia.

In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a study presented at ASCO21 that looked at the combination of ivosidenib and venetoclax with and without azacitidine for acute myeloid leukemia.

In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a new irreversible FLT3 inhibitor that was tested in a first-in-human study.

No methods or tests are available to detect susceptibility to acute lymphoblastic leukemia or lymphoblastic lymphomas. Likewise, there are no methodology or means to prevent these disorders.

Remission rates remained high with venetoclax and ibrutinib combination therapy after more than 3 years of follow-up among patients with previously untreated chronic lymphocytic leukemia, according to phase 2 study results in JAMA Oncology.

A blood-based test demonstrated efficacy and high specificity in detecting multiple cancer types with diverse biological features, paving the way for a new screening option, according to research published in Annals of Oncology.

In this video, Richard M Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute discusses three studies; one that looked at an irreversible inhibitor of FLT3 in patients with relapsed refractory acute myeloid leukemia (AML), and two studies that looked at approaches to Philadelphia and Philadelphia-like acute lymphoblastic leukemia. Stone highlighted the importance of the study on Adult Philadelphia-like B-cell ALL. "This is an important study because, if it is corroborated prospectively, it means that we can identify Philadelphia-like patients fairly easily with a fairly narrow panel of FISH-identifiable lesions.”